I(eye)-SCREEN: A real-world AI-based infrastructure for screening and prediction of progression in age-related macular degeneration (AMD) providing accessible shared care

I(eye)-SCREEN：基于人工智能的现实基础设施，用于筛查和预测年龄相关性黄斑变性 (AMD) 的进展，提供可及的共享护理

• 批准号: 10102692
• 金额: $ 41.25万
• 依托单位: QUEEN'S UNIVERSITY OF BELFAST
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10102692
• 关键词: eye; SCREEN; real; world; AI

The aim of I(eye)-Screen is to develop an artificial intelligence (AI)-based diagnostic decision support system for screening and monitoring of age-related macular degeneration (AMD) at an early stage before vision loss occurs. Late AMD is the leading cause of legal blindness >50 years with 110 mio individuals at risk. The multidisciplinary consortium brings together a network of clinical retina experts, computer scientists working at the cutting edge of AI development, an infrastructure of community-based opticians/optometrists and an SME experienced in digital platform performance to develop innovative and trustworthy AI tools for broad, real-time AMD screening and monitoring via a cloud-based infrastructure with unlimited access. To achieve the ambitious goal of finding “the needle in the haystack” in early AMD, Optical Coherence Tomography (OCT), a high-resolution, effortless imaging modality is used providing a detailed characterization of the retina in extensive volumetric scans. Breakthrough AI approaches for medical imaging will be developed to enable data-efficient and robust learning from sparse longitudinal OCT data to systematically analyse dense data volumes and identify (sub)clinical markers of disease activity. Clinical sites throughout Europe will collect a longitudinal cohort serving for calibrating and fine-tuning algorithms using the high-end OCT device available at eye clinics. Innovative AI technology will then be created to transferthe detection and monitoring tools to low-cost devices used in next door opticians’/optometrists’ offices. The timing of the project perfectly fits the recent regulatory approval of the first therapy to halt progression of the major atrophic type of AMD. The resulting AIbased “shared care” strategy offers unrestricted accessibility to vision-maintaining care with greatest health equity and provides a role model for screening for systemic, cardiovascular and neurodegenerative disease reflecting retinal biomarkers.

I(眼)-Screen的目的是开发一个基于人工智能(AI)的诊断决策支持系统，用于在视力丧失之前对老年性黄斑变性(AMD)进行早期筛查和监测。晚期AMD是导致法律失明的主要原因&50年来，1.1亿人处于危险之中。这个多学科联盟汇集了临床视网膜专家网络、在人工智能开发前沿工作的计算机科学家、社区验光师/验光师的基础设施以及在数字平台性能方面经验丰富的中小企业，以开发创新和值得信赖的人工智能工具，通过基于云的基础设施进行广泛、实时的AMD筛查和监测。为了实现在AMD早期发现“大海捞针”的雄心勃勃的目标，使用了光学相干断层扫描(OCT)，这是一种高分辨率、轻松的成像方式，在广泛的体积扫描中提供了视网膜的详细特征。将开发用于医学成像的突破性人工智能方法，以实现从稀疏的纵向OCT数据中进行数据高效和稳健的学习，以系统地分析密集数据量并识别疾病活动的(亚)临床标记。欧洲各地的临床站点将收集一个纵向队列，使用眼科诊所提供的高端OCT设备来校准和微调算法。然后，创新的人工智能技术将被创造出来，将检测和监测工具转移到隔壁配镜师/验光师办公室使用的低成本设备。该项目的时机完全符合最近监管部门批准的首个阻止主要萎缩型AMD进展的疗法。由此产生的基于人工智能的“共享护理”战略提供了不受限制地获得最大健康公平的视力维持护理，并为筛查反映视网膜生物标志物的系统性、心血管和神经退行性疾病提供了一个榜样。